KSP-QRH-E3-IRDye800

N/A

Report date: 2022/12/31 20:00:47

Base Information

Drug NameKSP-QRH-E3-IRDye800
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsCholangiocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Michigan
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Michigan
Inactive CompaniesN/A
Active IndicationsCholangiocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A